Pacira Pharm Inc PCRX

$36.39 +11.19 (44.40%)

Valuation

Market cap
986,983,000
Revenue TTM
$726,410,000
Net income TTM
$7,030,000
PE ratio
16.06
Forward PE
13.09
Profit margin
0.97%
Debt to equity
0.54

Trading

Volume
28,900,037
Avg volume
606,730
Day's range
$36.27 – $36.46
Shares out
39,862,000
Stochastic %K
44%
Beta
0.25
Analysts
Sell
Price target
$29.70

Price

Company profile

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the manage...

Show more

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
650 242 8052
Website
https://www.pacira.com
Address
2000 Sierra Point Parkway, Suite 900, Brisbane, United States

Latest news

Stocktwits

topstockalerts Oct 8, 9:28 PM
Top Gainers $FLYE $JZ $AIXI $PCRX $QNME
0 replies
CoffeeRocks Oct 8, 7:32 PM
$PCRX $VKTX $RXRX $SLS $ABCL VKTX WILL BE NEXT !!!$$$$
0 replies
topstockalerts Oct 8, 7:23 PM
Top Gainers $JZ $FLYE $AIXI $PCRX $OLB
0 replies
VerifiedLemon Oct 8, 7:21 PM
if you're looking for a free small caps community. Click below ⭐ Great bulls sharing ideas and finding the big runners early. Check it out 🫡💯 Bulls caught $PCRX $CIIT early now
0 replies
topstockalerts Oct 8, 6:43 PM
Top Gainers $JZ $FLYE $AIXI $OLB $PCRX
0 replies
KryptonResearch14 Oct 8, 6:05 PM
$PCRX Viatris is buying Pacira for 36.50 a share in cash, a 1.65 billion dollar deal announced this morning. The premium is 44.8 percent over Wednesday's 25.20 close. Shares are up about 44 percent to near 36.30, pacing the largest single-day gain on record (Barron's via Dow Jones Market Data). Trading a hair below the offer price is the market's verdict on a topping bid. Pacira brings real numbers: about 746 million in LTM revenue with adjusted EBITDA near 177 million, on Exparel and Zilretta product sales of 575.1 million and 116.6 million last year (per Viatris and Reuters). Viatris says the deal is immediately accretive with minimal impact on its leverage. One level down, this reads as rescue as much as bid. Pacira was in a multiyear decline and cut its sales outlook in August. Oppenheimer called the premium full price. The deal is expected to close by year end.
0 replies
topstockalerts Oct 8, 5:54 PM
Top Gainers $JZ $FLYE $AIXI $OLB $PCRX
0 replies
StocktwitsNews Oct 8, 5:48 PM
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today? $HAE $PCRX $VTRS https://stocktwits.com/news/equity/markets/hae-pcrx-stocks-hit-multi-year-highs-amid-broader-market-selloff/cZDUYkORBNz
0 replies